Comparative Pharmacology
Head-to-head clinical analysis: BACI RX versus SODIUM SULAMYD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACI RX versus SODIUM SULAMYD.
BACI-RX vs SODIUM SULAMYD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Sodium sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
1-2 drops of 10% or 15% solution into affected eye(s) every 2-3 hours initially, tapered as infection resolves; ophthalmic ointment: apply 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
None Documented
None Documented
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 mL/min.
7-13 hours (prolonged in renal impairment; in anuria up to 22-50 hours)
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Renal excretion of unchanged drug (approximately 70-100%) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic